DepYmed

DepYmed Inc. is a New York-based cancer and rare disease therapeutic development company. DepYmed is currently developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome. In addition to PTP1B inhibitors, DepYmed has developed a portfolio of novel small molecules with copper chelating properties which can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. DepYmed continues to develop the next generation of more potent PTP1B inhibitors as well as selective copper chelators which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory. DepYmed continues to explore additional indications that may benefit from using PTP1B inhibitors and selective copper chelators as therapeutic agents.

DepYmed headquartered in New York, United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $523.2M in funding across 48 round(s). With a team of 11-50 employees, DepYmed is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - DepYmed, raised $500.0K. Discover more about their projects, partnerships, and impact on our platform.